Genomic Data
Solutions for Pharma

Empowering Pharma R&D with Rare Disease Genomic Intelligence

Are you making multimillion-dollar decisions based
on incomplete genomic data?

Open-access resources like Google Scholar, ClinVar, and PubMed can miss evidence for up to 70% of clinically significant variants

In precision medicine, commonly used methods of gathering data fall short. If you are relying on data from incomplete resources, you are missing critical genomic data that can impact your entire program.

Incomplete genomic data puts drug programs at risk

The Wrong Variants

The Wrong Variants

Incomplete disease understanding and enrolling patients with the wrong genomic biomarkers dilutes trial results

Inaccurate Market Analysis

Inaccurate Market Analysis

Missing disease-causing variants underestimates prevalence, impairing investment, trial design, and pricing

Insufficient Diagnostic Data

Insufficient Diagnostic Data

Public databases don’t provide aggregate insights into diagnostic yield from genomic testing methods, labs, and the literature

Comprehensive genomic data de-risks drug programs

Genomenon combines AI and human expertise to deliver a comprehensive view of the genetics of your disease of interest, from discovery to commercialization

Understand Disease Mechanisms

Uncover pathogenic variants and relevant biomarkers to fully investigate genetic drivers of disease

Survey the Patient Universe

Review all published patient data annotated with demographic, genotype, phenotype, and CDx information

Validate Disease Prevalence

Estimate market potential with precise genetic evidence and up-to-date population databases

Increase Diagnostic Yield

Drive disease, trial & treatment awareness through our global network of clinical diagnostic labs

Get a comprehensive picture of your disease of interest

Genomic intelligence in action

Curation of the Entire Human Genome Requires the Best of Both Human and Artificial Intelligence (3:42 read)

Estimation of ENPP1 deficiency genetic prevalence using a comprehensive literature review and population databases (14:00 read)

Locus-Specific Patient Databases for Rare Disease: Patient Landscapes as Natural History Studies with Inozyme Pharma (56:00 watch)